Di Wu Yangyang Liu Xiaoting Li Yiying Liu Qifan Yang Yuting Liu Jingjing Wu Chen Tian Yulan Zeng Zhikun Zhao Yajie Xiao Feifei Gu Kai Zhang Yue Hu Li Liu
10.3389/fimmu.2020.01366
Front Immunol
2020 Jul 23;11:1366.
cancer immunotherapy epidermal growth factor receptor immune checkpoint blockade neoantigens tyrosine kinase inhibitor
CC BY
https://pubmed.ncbi.nlm.nih.gov/32793190/
Antigens, Neoplasm / immunology Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Carcinoma, Non-Small-Cell Lung / immunology Immune Checkpoint Inhibitors / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / genetics Lung Neoplasms / immunology Nivolumab / therapeutic use
Antigens, Neoplasm / immunology Carcinoma, Non-Small-Cell Lung / drug therapy Carcinoma, Non-Small-Cell Lung / genetics Carcinoma, Non-Small-Cell Lung / immunology Immune Checkpoint Inhibitors / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / genetics Lung Neoplasms / immunology Nivolumab / therapeutic use Case Reports Research Support, Non-U.S. Gov't Adult B7-H1 Antigen / antagonists & inhibitors ErbB Receptors / genetics Humans Male Mutation Antigens, Neoplasm B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors Nivolumab EGFR protein, human ErbB Receptors
PMC7390822
32793190
Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
2020